Company Filing History:
4 out of 525 
3 out of 3 
3 out of 560 
Years Active: 2013-2019
Title: The Innovative Contributions of Beatrice Yin in Cancer Therapy
Introduction: Beatrice Yin is a prominent inventor based in New York, NY, whose groundbreaking work has led to the development of four patents, significantly impacting the field of cancer therapy. Her latest innovations focus on the membrane transporter NaPi2b (SLC34A2) and its potential role in immunotherapy, particularly for ovarian cancer.
Latest Patents: Beatrice Yin's latest patents explore the utility of antibodies directed towards the membrane transporter NaPi2b (SLC34A2) for therapeutic applications. These patents detail the identification of an epitope peptide within the SLC34A2 protein that has been linked to ovarian cancer. The claims include methods for generating antibodies that provide anti-tumor or anti-cancer activity and stimulate an immunological response. In addition, the patents describe techniques for screening and identifying compounds targeting the SLC34A2 epitope peptide, highlighting a promising avenue for cancer treatment.
Career Highlights: Beatrice has established her career through significant contributions while working with reputable institutions, including the Ludwig Institute for Cancer Research Limited and the Institute of Molecular Biology and Genetics of the National Academy of Science of Ukraine. Her expertise in molecular biology and genetics has guided her innovative research and development efforts.
Collaborations: Throughout her career, Beatrice Yin has collaborated with esteemed colleagues such as Gerd J Ritter and Anne Murray. These collaborations have facilitated the advancement of her research, leading to a broader understanding and exploration of cancer therapies targeting SLC34A2.
Conclusion: Beatrice Yin's innovative work in identifying the therapeutic potential of NaPi2b (SLC34A2) represents a significant advancement in the field of cancer treatment. Her contributions through patents not only highlight her commitment to scientific research but also pave the way for new therapeutic strategies aimed at improving patient outcomes in oncology.